Vera Therapeutics (VERA)
(Delayed Data from NSDQ)
$37.51 USD
+1.85 (5.19%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $37.49 -0.02 (-0.05%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth A Momentum D VGM
Balance Sheet
Fiscal Year End for Vera Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 161 | 115 | 80 | 54 | 3 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 11 | 11 | 3 | 1 | 0 |
Total Current Assets | 172 | 126 | 83 | 54 | 4 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 1 |
Investments & Advances | 0 | 0 | 1 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 176 | 131 | 84 | 55 | 5 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 11 | 12 | 1 | 1 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 9 | 11 | 6 | 1 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 1 | 0 |
Total Current Liabilities | 22 | 26 | 8 | 2 | 1 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 50 | 25 | 5 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 2 | 2 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 74 | 55 | 14 | 4 | 2 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 140 | 40 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 410 | 290 | 194 | 2 | 1 |
Retained Earnings | -309 | -213 | -124 | -91 | -38 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 102 | 77 | 70 | 50 | -37 |
Total Liabilities & Shareholder's Equity | 176 | 131 | 84 | 55 | 5 |
Total Common Equity | 102 | 77 | 70 | -89 | -77 |
Shares Outstanding | 52.50 | 27.80 | 21.20 | NA | NA |
Book Value Per Share | 1.94 | 2.77 | 3.28 | 0.00 | 0.00 |
Fiscal Year End for Vera Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 384 | 404 | 161 | 160 | 181 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 10 | 13 | 11 | 12 | 10 |
Total Current Assets | 395 | 416 | 172 | 172 | 191 |
Net Property & Equipment | 0 | 0 | 0 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 397 | 419 | 176 | 176 | 195 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 5 | 5 | 11 | 12 | 13 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 12 | 7 | 9 | 10 | 11 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 18 | 15 | 22 | 25 | 27 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 50 | 50 | 50 | 25 | 25 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 69 | 66 | 74 | 52 | 55 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 699 | 691 | 410 | 407 | 404 |
Retained Earnings | -371 | -337 | -309 | -283 | -263 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 328 | 354 | 102 | 124 | 141 |
Total Liabilities & Shareholder's Equity | 397 | 419 | 176 | 176 | 195 |
Total Common Equity | 328 | 354 | 102 | 124 | 141 |
Shares Outstanding | 54.80 | 54.40 | 52.50 | 44.40 | 44.30 |
Book Value Per Share | 5.98 | 6.50 | 1.94 | 2.79 | 3.17 |